This HTML5 document contains 81 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00287/identifier/chebi/
n23http://linked.opendata.cz/resource/AHFS/
n25http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n9http://linked.opendata.cz/resource/drugbank/dosage/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00287/identifier/pharmgkb/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00287/identifier/wikipedia/
n28http://bio2rdf.org/drugbank:
n21http://linked.opendata.cz/resource/drugbank/drug/DB00287/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00287/identifier/pubchem-substance/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00287/identifier/kegg-drug/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00287/identifier/drugbank/
n5http://linked.opendata.cz/resource/drugbank/patent/
n29http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n19http://www.drugs.com/cdi/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00287/identifier/national-drug-code-directory/
n24http://www.rxlist.com/cgi/generic2/
n6http://linked.opendata.cz/resource/drugbank/property/
n8http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/ontology/sukl/drug/
n14http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00287/identifier/chemspider/

Statements

Subject Item
n2:DB00287
rdf:type
n3:Drug
n3:description
Travoprost ophthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a synthetic prostaglandin F2alpha analogue. [Wikipedia]
n3:dosage
n9:271B4AD3-363D-11E5-9242-09173F13E4C5 n9:271B4AD2-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Lim KS, Nau CB, O'Byrne MM, Hodge DO, Toris CB, McLaren JW, Johnson DH: Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008 May;115(5):790-795.e4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18452763 # Costagliola C, dell'Omo R, Romano MR, Rinaldi M, Zeppa L, Parmeggiani F: Pharmacotherapy of intraocular pressure - part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother. 2009 Dec;10(17):2859-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19929706 # Ferrari G, Scagliotti GV: Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients. Eur J Cancer. 1996 Dec;32A(13):2368-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9038626 # Toris CB, Gabelt BT, Kaufman PL: Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008 Nov;53 Suppl1:S107-20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19038618 # Arranz-Marquez E, Teus MA: Prostanoids for the management of glaucoma. Expert Opin Drug Saf. 2008 Nov;7(6):801-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18983226
n3:group
approved
n3:halfLife
Terminal elimination half-life of travoprost free acid is 45 minutes.
n3:indication
Ophthalmic solution used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication.
n3:manufacturer
n25:271B4AC9-363D-11E5-9242-09173F13E4C5
owl:sameAs
n28:DB00287 n29:DB00287
dcterms:title
Travoprost
adms:identifier
n11:Travoprost n12:4445407 n15:DB00287 n16:PA164781371 n17:746859 n18:0065-0266-25 n20:D01964 n21:5282226 n22:46507637
n3:mechanismOfAction
Travoprost free acid is a selective FP prostanoid receptor agonist and is believed to reduce intraocular pressure by increasing the drainage of aqueous humor, which is done primarily through increased uveoscleral outflow and to a lesser extent, trabecular outflow facility.
n3:packager
n25:271B4AC7-363D-11E5-9242-09173F13E4C5 n25:271B4AC8-363D-11E5-9242-09173F13E4C5 n25:271B4AC6-363D-11E5-9242-09173F13E4C5
n3:patent
n5:5631287 n5:6503497 n5:2181172 n5:2129287
n3:routeOfElimination
Less than 2% of the topical ocular dose of travoprost was excreted in the urine within 4 hours as the travoprost free acid.
n3:synonym
Travoprost Travatan Z Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1e,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate Travatan Travoprostum
n3:toxicity
Symptoms of overexposure include irritation to the skin, eyes, nose, throat, and respiratory tract.
n13:hasAHFSCode
n23:52-92-00
foaf:page
n8:tra1596.shtml n19:travoprost-drops.html n24:travoprost.htm
n3:IUPAC-Name
n6:271B4AD8-363D-11E5-9242-09173F13E4C5
n3:InChI
n6:271B4ADE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n6:271B4ADD-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n6:271B4ADA-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n6:271B4ADB-363D-11E5-9242-09173F13E4C5
n3:SMILES
n6:271B4ADC-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n6:271B4AD6-363D-11E5-9242-09173F13E4C5 n6:271B4AEE-363D-11E5-9242-09173F13E4C5
n3:logP
n6:271B4AD7-363D-11E5-9242-09173F13E4C5 n6:271B4AD4-363D-11E5-9242-09173F13E4C5 n6:271B4AEF-363D-11E5-9242-09173F13E4C5
n3:logS
n6:271B4AD5-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n14:S01EE04
n3:H-Bond-Acceptor-Count
n6:271B4AE4-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n6:271B4AE5-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n6:271B4ADF-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n6:271B4AE0-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n6:271B4AE2-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n6:271B4AE1-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n6:271B4AE3-363D-11E5-9242-09173F13E4C5
n3:absorption
Systemically absorbed when administered to the eye.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
157283-68-6
n3:category
n3:containedIn
n4:271B4AD0-363D-11E5-9242-09173F13E4C5 n4:271B4AD1-363D-11E5-9242-09173F13E4C5 n4:271B4ACE-363D-11E5-9242-09173F13E4C5 n4:271B4ACF-363D-11E5-9242-09173F13E4C5 n4:271B4ACC-363D-11E5-9242-09173F13E4C5 n4:271B4ACD-363D-11E5-9242-09173F13E4C5 n4:271B4ACA-363D-11E5-9242-09173F13E4C5 n4:271B4ACB-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n6:271B4AEA-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n6:271B4AEC-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n6:271B4AED-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n6:271B4AE9-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n6:271B4AE8-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n6:271B4AEB-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n6:271B4AD9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n6:271B4AE6-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n6:271B4AE7-363D-11E5-9242-09173F13E4C5